TG Therapeutics, Inc.
IT ˙ BIT ˙ US88322Q1085
34,00 € 0,00 (0,00%)
2026-06-05
DEL PRIS
SecurityIT:1TGTX / TG Therapeutics, Inc.
InstitutionComerica Bank
Latest Disclosed Ownership31,100 shares
Latest Disclosed Value $ 927,081
Comerica Bank reports 23.91% decrease in ownership of 1TGTX / TG Therapeutics, Inc.

On January 29, 2026 - Comerica Bank filed a 13F-HR form disclosing ownership of 31,100 shares of TG Therapeutics, Inc. (IT:1TGTX) valued at $822,440 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 40,872 shares of TG Therapeutics, Inc.. This represents a change in shares of -23.91% during the quarter. The current value of the position is $1,057,400 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F TG THERAPEUTICS COM 88322Q108 31,100 -9,772 -23.91 927 -37.20 0.0037
2025-11-14 2025-09-30 13F TG THERAPEUTICS COM 88322Q108 40,872 -5,783 -12.40 1,477 -12.09 0.0056
2025-08-14 2025-06-30 13F TG THERAPEUTICS COM 88322Q108 46,655 1,352 2.98 1,679 -5.99 0.0065
2025-05-14 2025-03-31 13F TG THERAPEUTICS COM 88322Q108 45,303 -1,425 -3.05 1,786 27.03 0.0075
2025-02-14 2024-12-31 13F/A-1 TG THERAPEUTICS COM 88322Q108 46,728 94 0.20 1,407 28.99 0.0057
2025-02-14 2024-12-31 13F TG THERAPEUTICS COM 88322Q108 46,728 94 1,407 0.0047
2024-11-14 2024-09-30 13F TG THERAPEUTICS COM 88322Q108 46,634 46,634 1,091 0.0043
2024-02-14 2023-12-31 13F TG THERAPEUTICS COMMON 88322Q108 0 -467 -100.00 0 -100.00
2023-11-21 2023-09-30 13F TG THERAPEUTICS COMMON 88322Q108 467 467 4 0.0000
2022-02-18 2021-12-31 13F TG THERAPEUTICS COM 88322Q108 0 -226,460 -100.00 0 -100.00
2021-11-22 2021-09-30 13F TG THERAPEUTICS COM 88322Q108 226,460 35,080 18.33 7,111 70.61 0.0428
2021-08-26 2021-06-30 13F TG THERAPEUTICS COM 88322Q108 191,380 191,380 4,168 0.0249
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.